Trevi Therapeutics | 10-Q:季度報表
Trevi Therapeutics | 8-K:Trevi Therapeutics公佈2024年第一季度財務業績並提供業務最新情況
Trevi Therapeutics | ARS:年度報告
Trevi Therapeutics | DEFA14A:其他
Trevi Therapeutics | DEF 14A:股東委託書決議
Trevi Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Rosalind Advisors, Inc.(1.34%),Steven Salamon(1.34%)等
Trevi Therapeutics | 8-K:Trevi Therapeutics公佈2023年第四季度和年終財務業績並提供業務最新情況
Trevi Therapeutics | 10-K:年度報表
Trevi Therapeutics | S-8:員工福利計劃證券登記
Trevi Therapeutics | 4:持股變動聲明-高管 Simon Farrell
Trevi Therapeutics | 4:持股變動聲明-高管 Galletta Christopher
Trevi Therapeutics | 4:持股變動聲明-高管 Clark David J
Trevi Therapeutics | 4:持股變動聲明-高管 GOOD JENNIFER L
Trevi Therapeutics | 4:持股變動聲明-高管 SCIASCIA THOMAS
Trevi Therapeutics | 4:持股變動聲明-高管 Delfini Lisa
Trevi Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Venrock Healthcare Capital Partners II, L.P.(9.99%),VHCP Co-Investment Holdings II, LLC(9.99%)等
Trevi Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Fairmount Funds Management LLC(0.0%),Peter Harwin(0.0%)等
Trevi Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Viking Global Investors LP(9.99%),Viking Global Opportunities Parent GP LLC(9.99%)等
Trevi Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Rubric Capital Management LP(8.90%),David Rosen(8.90%)
Trevi Therapeutics:2023財年三季報
暫無數據